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Abstract Knowledge about potential differences in infarct
tissue characteristics between patients with prior life-
threatening ventricular arrhythmia versus patients receiving
prophylactic implantable cardioverter-defibrillator (ICD)
might help to improve the current risk stratification in
myocardial infarction (MI) patients who are considered for
ICD implantation. In a consecutive series of (ICD) recipients
for primary and secondary prevention following MI, we used
contrast-enhanced (CE) cardiovascular magnetic resonance
(CMR) imaging to evaluate differences in infarct tissue
characteristics. Cine-CMR measurements included left
ventricular end-diastolic and end-systolic volumes (EDV,
ESV), left ventricular ejection fraction (LVEF), wall motion
score index (WMSI), and mass. CE-CMR images were
analyzed for core, peri, and total infarct size, infarct locali-
zation (according to coronary artery territory), and trans-
mural extent. In this study, 95 ICD recipients were included.
In the primary prevention group (n = 66), LVEF was lower
(23 ± 9 % vs. 31 ± 14 %; P \ 0.01), ESV and WMSI were
higher (223 ± 75 ml vs. 184 ± 97 ml, P = 0.04, and
1.89 ± 0.52 vs. 1.47 ± 0.68; P \ 0.01), and anterior infarct
localization was more frequent (P = 0.02) than in the sec-
ondary prevention group (n = 29). There were no differ-
ences in infarct tissue characteristics between patients
treated for primary versus secondary prevention (P [ 0.6 for
all). During 21 ± 9 months of follow-up, 3 (5 %) patients in
the primary prevention group and 9 (31 %) in the secondary
prevention group experienced appropriate ICD therapy for
treatment of ventricular arrhythmia (P \ 0.01). There was
no difference in infarct tissue characteristics between
recipients of ICD for primary versus secondary prevention,
while the secondary prevention group showed a higher fre-
quency of applied ICD therapy for ventricular arrhythmia.
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Introduction
Ventricular arrhythmia (VA) is a major cause of sudden
cardiac death (SCD) in patients with prior myocardial
infarction (MI) [1]. Several randomized trials have shown a
beneficial effect of implantable cardioverter-defibrillator
(ICD) therapy among MI patients with prior life-threaten-
ing VA (secondary prevention) [2–4]. In the setting of
prophylactic ICD therapy (primary prevention), left ven-
tricular ejection fraction (LVEF) below 35 % is considered
an indication for ICD implantation. However, \25 % of
these ICD recipients actually experience a life-threatening
VA requiring shock therapy during median follow-up of
45.5 months [5]. Current guidelines consider a low LVEF
post-MI as the most important criterion to determine a
patient’s eligibility. Therefore, these guidelines appear to
be suboptimal [1]. Better risk stratification is warranted to
reduce the number of unnecessary device implantations,
especially in the setting of primary prevention [3, 5–7].
Cardiovascular magnetic resonance (CMR) imaging in
combination with the contrast-enhancement (CE) tech-
nique allows the accurate assessment of LV geometry and
function as well as tissue characteristics. This permits
accurate assessment of size, heterogeneity, and transmu-
rality of the myocardial scar [8, 9]. Infarct tissue charac-
teristics (e.g. localization, heterogeneity) [10–13] are
considered potential predictors of life-threatening VAs, and
could play a role in risk stratification before ICD implan-
tation [8, 9, 14].
Previous studies demonstrated a higher occurrence of
VA (and thus a higher incidence of appropriate ICD ther-
apy) in ICD recipients for secondary prevention compared
to patients who received an ICD in the setting of primary
prevention [2, 15–18]. Insight into potential differences in
infarct tissue characteristics between ICD recipients for
primary versus secondary prevention may potentially help
to improve the current practice of risk stratification in MI
patients considered for ICD implantation, specifically in
the primary prevention group.
Therefore, in a consecutive series of ICD recipients for
primary and secondary prevention following MI, we used
CE-CMR to evaluate potential differences in infarct tissue
characteristics.
Methods
Patient population
The study was conducted at Medisch Spectrum Twente,
Enschede, the Netherlands. A consecutive series of patients
with prior MI, who received an ICD for primary or
secondary prevention following current guidelines of the
Dutch (NVVC) and European society of Cardiology (ESC)
in which the LVEF was determined based on echocardio-
graphic findings, was assessed. The referring physicians
had no access to the CMR report before defining thera-
peutic management. Prior to ICD implantation, these
patients were referred for CMR to assess left ventricular
(LV) dimension and function, and after intravenous injec-
tion of gadolinium, characterization of the infarcted tissue.
According to current guidelines, the patients who received
ICD treatment for primary prevention had an indication
based on a LVEF B 35 % (majority of patients) or the
presence of spontaneous ventricular tachycardia, even with
a somewhat more preserved LV function. Patients were
only included in the study if the MI occurred at least 1
month prior to CMR (according to the definition of a
healed MI [19] and a positive infarct pattern on CE
imaging was found. The study was approved by the local
ethics committee and informed consent was obtained.
As the secondary prevention group (dissimilar to the
primary prevention group) was not selected based on a
particularly low ejection fraction, the mean LVEF of this
group may be expected to be higher. To correct for this
potential confounder, ICD recipients from both groups with
a LVEF B 35 % were separately compared. A comparable
subgroup analysis in ICD recipients with a LVEF [ 35 %
was not performed as the limited number of patients did not
permit a meaningful analysis.
CMR data acquisition
CMR examination was performed on a 1.5-T whole body
scanner (Achieva scan, Philips Medical System, Best, the
Netherlands) using commercially available software. For
signal-reception a five-element cardiac synergy coil was
used. Electrocardiogram triggering was performed with a
vector-electrocardiogram set-up. Subjects were examined
in the supine position. Cine (morphologic) images in the
cardiac short-axis, four-chamber, three-chamber, two-
chamber long-axis, and LV outflow tract views were
acquired by using fast field echo cine images. (Slice
thickness 8.0 mm, repetition time 3.4 ms; echo time
1.7 ms; flip angle 60; matrix 256 9 256).
Myocardial scar was assessed on CE multislice short-
axis, long-axis and four-chamber views, obtained 10 min
after intravenous bolus injection of 0.2 mmol gadolinium/
kg body weight (Shering AG, Berlin, Germany). A three-
dimensional Turbo Field Echo-inversion recovery T1-
weighted sequence was used with the following parame-
ters: repetition time 4.0 ms; echo time 1.3 ms; flip angle
15; inversion time individually optimized to null myo-
cardial signal (usually between 180 and 250 ms); matrix
157; and slice thickness 10 mm.
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CMR data analysis and definitions
CMR data were analyzed on a workstation using dedicated
software (Philips MR workspace, Release 2.5.3.0; the
Netherlands). Analysis was performed by reviewers blin-
ded to clinical information.
LV geometry and function
Left ventricular end-diastolic and end-systolic volumes
(EDV and ESV; ml), left ventricular ejection fraction
(LVEF; %), and end-diastolic wall mass (EDWM; g) were
calculated from contiguous short-axis loops by segmenta-
tion of endocardial and epicardial borders on each frame.
Body surface area adjusted EDV (EDVi), ESV (ESVi) and
EDWM (EDWMi) were also calculated.
The left ventricular wall regions were further divided
into 17 segments according to a standardized myocardial
segmentation model [20]. Normal wall motion was
assigned a score 0, hypokinesia 1, severe hypokinesia 2,
akinesia 3, and dyskinesia 4. The wall motion score index
(WMSI) was calculated by dividing the sum of scores in
each segment by the total number of observed segments.
Infarct tissue characteristics
Infarcted myocardium was defined as the zone of hype-
renhancement on the CE images, in contrast with the dark-
gray signal of normal myocardium (Fig. 1). Infarct size
was quantified by a semi-automatic thresholding technique
with the full width at half maximum approach as previ-
ously validated [21]. After outlining the myocardial seg-
ment containing the region with high signal intensity, the
maximum signal intensity region was determined. Scar was
divided into an infarct core zone and a heterogeneous zone
(i.e. peri-infarct zone). Infarct core was then defined as
myocardium with a signal intensity C50 % of the maximal
signal intensity. The heterogeneous zone was defined as
myocardium with a signal intensity between C35 and
\50 % of maximal signal intensity. Total scar was defined
as the sum of infarct core plus heterogenous zone.
Scar tissue characteristics were further quantified
according to location by use of a 17 segmental model [20].
Each segment was scored as follows: a scar score of 0 was
defined normal, 1 as 1–25 % scar, 2 as 26–50 % scar, 3 as
51–75 % scar, and 4 as 76–100 % scar of the segmental area.
The transmural extent of myocardial scar was defined as
the number of segments with a scar score 3 or 4 [22]. In
addition, a segmental regional scar score was calculated in
order to relate scar size to the territories of the three major
coronary arteries as previously described in detail [20].
Follow up and definition of events
Follow-up was performed by our outpatient clinic,
including registration of the occurrence of events and
survival status. Regular device interrogation was scheduled
every 3–6 months. In case of any experienced event, an
additional device interrogation was performed. Device
therapy was classified as appropriate or inappropriate.
Appropriate ICD therapy was defined as anti-tachycardia
pacing and/or appropriate shock in response to ventricular
tachycardia or ventricular fibrillation. For the purpose of
this study, only appropriate device therapies were consid-
ered as arrhythmic events. Mortality was reported and
causes of death were scored as follows: (1) myocardial
infarction, (2) heart failure, (3) cerebrovascular accident,
(4) carcinoma, or (5) other causes of death.
Fig. 1 CE-CMR of a secondary prevention patient with a previous MI. a Short-axis view showing contrast-enhancement inferoseptal, inferior
and inferolateral. b Long-axis view showing contrast-enhancement inferior
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A major cardiovascular event (MACE) was defined as
appropriate ICD therapy and/or death.
Statistical analysis
Continuous variables had a normal distribution and were
expressed as mean ± SD. Categorical data were expressed as
frequencies and percentages. To compare the primary and
secondary prevention groups, Student’s t test and Mann–
Whitney U test were used to compare continuous variables,
and Chi-square test and Fisher exact test were used to compare
categorical variables. A survival analysis was performed to
investigate if the association between infarct tissue charac-
teristics with MACE is different among groups (ICD for
primary preventions vs. ICD for secondary prevention). A
P value\ 0.05 was considered statistically significant.
Results
Study patients
In this study, 95 patients (64 ± 10 years old; 79 men) with
a median of 141 (1–434) months after MI were examined.
A total of 66 patients received an ICD for primary pre-
vention and 29 patients for secondary prevention. Indica-
tion for secondary prevention by ICD implantation was
(1) SCD in 14 patients (48 %) or (2) VT episodes in 15
patients (52 %). Time between events and ICD implanta-
tion was on average 2 weeks (median). (25th percentile
1 week, 50th percentile 2 weeks, 75th percentile weeks). In
general, ICD implantation was performed shortly after CE-
CMR assessment; the average (median) within 1 week, the
75th percentile within 1 week and the 90th percentile
within 5.4 weeks. Demographics and baseline characteris-
tics did not differ between groups except for diuretic usage
(80 % vs. 45 %; P \ 0.01). Patient demographics are
presented in Table 1, which also shows a subgroup of
patients with LVEF B 35 %.
CMR results
LV geometry and function
In the primary prevention group, LVEF (23 ± 9 % vs.
31 ± 14 %; P \ 0.01) was significantly lower while ESVi
(113 ± 39 ml vs. 91 ± 49 ml; P = 0.03) and WMSI
(1.89 ± 0.52 vs. 1.47 ± 0.68; P \ 0.01) were significantly
higher than in the secondary prevention group (Table 2).
Infarct characteristics
There were no significant differences between size of the
infarct core (12 ± 7 % vs. 11 ± 9 %; P = 0.62), size of
Table 1 Patients characteristics
All patients Patients with LVEF B 35 %
Primary prevention
(n = 66)
Secondary prevention
(n = 29)
P Primary prevention
(n = 60)
Secondary prevention
(n = 20)
P
Male sex, n 56 (85) 23 (79) 0.56 52 (87) 16 (80) 0.48
Age, years 65 ± 9 61 ± 11 0.09 66 ± 8 62 ± 9 0.08
Hypertension 24 (36) 11 (38) 1.00 22 (37) 8 (40) 1.00
Diabetes 18 (27) 5 (17) 0.43 17 (28) 3 (15) 0.25
Medication
B-blocker 59 (89) 23 (79) 0.21 53 (88) 16 (80) 0.45
Ace inhibitor 50 (76) 20 (69) 0.62 43 (72) 16 (80) 0.57
Diuretic 53 (80) 13 (45) \0.01 48 (80) 12 (60) 0.13
Statin 58 (88) 28 (97) 0.27 54 (90) 20 (100) 0.33
Infarct
Single 56 (84) 24 (83) 0.87 51 (85) 17 (85) 0.67
Multiple 5 (8) 2 (7) 5 (8) 2 (10)
Unknown 5 (8) 3 (10) 4 (7) 1 (5)
Infarct localization 0.08 0.15
Anterior 33 (50) 10 (35) 28 (47) 6 (30)
Nonanterior 18 (27) 14 (48) 17 (28) 9 (45)
Both 15 (23) 5 (17) 15 (25) 5 (25)
Infarct age, months 133 (1–434) 166 (1–426) 0.24 155 (1–434) 209 (13–426) 0.07
Continuous data are expressed as mean ± SD or median with range; and categorical data as frequencies and percentage
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the peri-infarct (10 ± 4 % vs. 10 ± 5 %; P = 0.70), total
infarct size (24 ± 10 % vs. 21 ± 12 %; P = 0.62) and
transmural extent (3.19 ± 2.41 vs. 2.97 ± 2.76; P = 0.70)
of the infarct (Fig. 2). According to the regional scar score,
left anterior descending scar score (1.55 ± 0.81 vs.
1.08 ± 0.84; P = 0.02) was significantly higher in the
primary prevention group (Table 2).
CMR results in subgroup of patients
with LVEF B 35 %
In order to correct for the difference in LVEF between the
primary and secondary prevention group (Table 2), patients
with an LVEF B 35 % were included in a subanalysis. There
was no difference in demographics and baseline characteris-
tics of the remaining 60 and 20 patients, respectively.
According to LV geometry and function as well as CE-CMR
assessed infarct tissue characterization, no significant differ-
ences were observed between primary and secondary pre-
vention patients with an LVEF B 35 % (Table 2).
CMR results according to infarct localization
As infarct localization differed between the primary and
secondary prevention group (Tables 1 and 2), patients were
stratified according to infarct localization. Between the 33
and 10 patients with anterior wall MI, respectively, there
was no significant difference in LV dimensions, LV func-
tion, or infarct tissue characteristics (Table 3). Among
patients with non-anterior infarct localization, the primary
prevention group (n = 18) showed a lower LVEF
(22 ± 9 % vs. 31 ± 14 %; P = 0.04) and a higher WMSI
(2.10 ± 0.52 vs. 1.47 ± 0.50; P \ 0.01) than the second-
ary prevention group (n = 14); but there was no significant
difference in infarct tissue characteristics (Table 3).
Follow-up
During 21 ± 9 months of follow-up, 4 patients in the pri-
mary prevention group and 4 patients in the secondary
prevention group died, respectively. All 8 patients died on
heart failure. The frequency of appropriate ICD therapy
differed significantly between the primary and secondary
prevention group (3/66 (5 %) vs. 9/29 (31 %); P \ 0.01).
In the primary prevention group, only appropriate shock
therapy (2 on VF, 1 on VT) was delivered, while in the
secondary prevention group both appropriate shock therapy
(n = 3; all on VT) and antitachycardia pacing (n = 6)
were delivered. All but 2 patients with appropriate ICD
therapy (both secondary prevention) had a B35 %.
Table 2 CMR characteristics in all patients and in the subgroup of patients with LVEF B 35 %
All patients Patients with LVEF B 35
Primary prevention
(n = 66)
Secondary prevention
(n = 29)
P Primary prevention
(n = 60)
Secondary prevention
(n = 20)
P
LV geometry and function
EDV 284 ± 72 259 ± 91 0.16 293 ± 68 288 ± 95 0.81
EDVi 144 ± 38 129 ± 45 0.09 150 ± 34 144 ± 45 0.53
ESV 222 ± 75 184 ± 97 0.04 231 ± 69 225 ± 63 0.54
ESVi 113 ± 39 91 ± 49 0.03 119 ± 35 111 ± 47 0.43
EDWM 145 ± 37 143 ± 34 0.79 148 ± 37 141 ± 32 0.46
EDWMi 37 ± 10 36 ± 9 0.66 75 ± 18 73 ± 17 0.63
LVEF 23 ± 9 31 ± 14 \0.01 22 ± 7 23 ± 7 0.31
WMSI 1.89 ± 0.52 1.47 ± 0.68 \0.01 1.96 ± 0.48 1.76 ± 0.47 0.11
Infarct characteristics
Infarct size-core% 12 ± 7 11 ± 9 0.62 12 ± 7 13 ± 9 0.58
Infarct size-peri% 10 ± 4 10 ± 5 0.70 10 ± 4 11 ± 5 0.53
Infarct size-total% 24 ± 10 21 ± 12 0.62 23 ± 10 24 ± 13 0.52
Infarct localization
LAD score 1.55 ± 0.81 1.08 ± 0.84 0.02 1.54 ± 0.82 1.25 ± 0.86 0.23
RCA score 1.30 ± 0.86 1.53 ± 0.97 0.28 1.30 ± 0.85 1.62 ± 1.01 0.19
RCX score 1.10 ± 0.89 1.07 ± 0.76 0.92 1.07 ± 0.85 1.14 ± 0.86 0.80
Transmural extent 3.19 ± 2.41 2.97 ± 2.76 0.70 3.11 ± 2.46 3.55 ± 2.91 0.52
Data are presented as mean ± SD or median with range. Categorical data are presented as frequencies and percentages
EDV end diastolic volume, ESV end systolic volume, EDWM end diastolic wall mass, LVEF left ventricular ejection fraction, WMSI wall motion
score index, LAD left anterior descending, RCA right coronary artery, LCX left circumflex
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Patients with appropriate ICD therapy did not differ
from patients without event in peri-infarct size (8.83 ±
3.20 % vs. 10.51 ± 4.39 %; P = 0.20), but core infarct
size was smaller in patients with events (8.00 ± 4.93 % vs.
12.58 ± 7.37 %; P = 0.040).
The association between infarct tissue characteristics
with MACE did not significantly differ among groups (ICD
for primary prevention vs. ICD for secondary prevention)
(P = 0.25–0.91).
Discussion
The implantation of ICD in MI patients provides protection
from SCD following VA. When current guidelines are
followed, \1 out of 4 primary prevention ICD recipients
experiences actual life-threatening VA requiring shock
therapy during a follow-up period of almost 4 years [5].
This shows that there may be some room for improvement
in the selection of ICD candidates in the setting of primary
prevention.
The infarct core and heterogeneous zone, as well as
presence of transmural infarction may serve as an anatomic
pathway for reentry, and consequently, the occurrence of
VA [10–13, 23, 24]. In this respect, it has recently been
demonstrated that a larger size of infarct heterogeneity is
related to increased ventricular irritability by programmed
electrical stimulation as well as spontaneous VA [8, 9].
While there was a difference in frequency of applied
ICD therapy between primary and secondary prevention
patients in our study, there was no difference in the size of
the infarct tissue characteristics between these two sub-
populations of patients. These findings may question the
importance of the size of infarct tissue characteristics as a
predictor of life-threatening VA [25]. However, size of
infarct tissue characteristics is not really all that matters, as
it has been demonstrated that a substantial portion of
tachycardia originates from reentry occurring in a very
small circuit extending just over a few millimeters [26].
Other factors than anatomic substrate may interfere with
the risk of VA in the setting of MI; an example may be
Fig. 2 LVEF and infarct tissue characteristics (mean ± SD) in
primary and secondary prevention patients. While in primary versus
secondary prevention patients LVEF differed significantly, there were
no significant differences in infarct tissue characteristics
Table 3 CMR characteristics in all patients stratified according to infarct localization
Anterior infarction Nonanterior infarction
Primary prevention
(n = 33)
Secondary prevention
(n = 10)
P Primary prevention
(n = 18)
Secondary prevention
(n = 14)
P
LV geometry and function
EDV 282 ± 79 275 ± 106 0.83 286 ± 67 250 ± 90 0.20
EDVi 144 ± 40 135 ± 50 0.56 149 ± 35 126 ± 48 0.17
ESV 218 ± 81 192 ± 119 0.43 225 ± 75 180 ± 99 0.15
ESVi 111 ± 41 95 ± 58 0.31 117 ± 40 90 ± 53 0.15
EDWM 137 ± 42 140 ± 34 0.83 158 ± 29 145 ± 32 0.24
EDWMi 71 ± 21 69 ± 15 0.81 82 ± 14 75 ± 19 0.26
LVEF 25 ± 9 32 ± 17 0.22 22 ± 9 31 ± 14 0.04
WMSI 1.73 ± 0.52 1.51 ± 0.89 0.32 2.04 ± 0.56 1.36 ± 0.62 \0.01
Infarct characteristics
Infarct size-core% 12 ± 6 11 ± 9 0.47 11 ± 6 10 ± 7 0.62
Infarct size-peri% 11 ± 4 11 ± 6 0.77 9 ± 3 9 ± 5 0.80
Infarct size-total% 23 ± 9 22 ± 14 0.71 21 ± 9 19 ± 11 0.65
Transmural extent 3.29 ± 2.22 2.80 ± 2.90 0.58 3.60 ± 0.47 2.79 ± 2.69 0.40
See legend of Table 2 for details
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genetic factors. In this respect, recently, a genome-wide
association study identified in patients with a first MI a
gene locus prone for ventricular fibrillation [27].
In the primary prevention group, we found a substan-
tially larger amount of MI tissue in the anterior wall of the
LV during CMR assessment. Several clinical studies
observed that patients with anterior MI usually have a
worse LVEF [28]. The larger amount of anterior MI in the
primary prevention group may thus actually be expected, as
LVEF below 35 % is used as a major risk stratifier for
primary prevention with ICD, according to current guide-
lines. In addition, in our primary prevention group
(P \ 0.01) there was a higher use of diuretics for symp-
tomatic treatment of heart failure. On the other hand,
secondary prevention patients—patients who already had a
life-threatening VA in the past—showed more appropriate
ICD therapies during follow-up, as may be expected based
on the difference in indication. Thus, there must be other
factors than the studied CMR characteristics involved to
make the myocardium prone to the development of life-
threatening VA.
With current clinically applied CE-CMR technology,
spatial resolution imposes constraints on what type of tis-
sue is concealed within the peri-infarct zone, characterized
by intermediate signal intensities [29]. High-resolution CE-
CMR imaging with 1,000-fold higher resolution than
clinical scans may bear the potential to obtain further
insights in an experimental setting [30]. There is a lack of
well-defined gold standard formula for the assessment of
infarcted myocardium. Partial volume effects and blurred
images by cardiac motion during image acquisition may
lead to a relative increase of signal intensity in pixels of the
border zone of infarcted compared to remote myocardium,
which may lead to an overestimation of the total scar score.
Initial visual assessment, manual tracing of endo and epi-
cardial contours, visual identification of the region of
interest with maximum signal intensity, and visual check
for erroneous inclusion of other regions with high signal
intensity (e.g. in/folding or motion artefacts, fat, or peri-
cardial effusion) [31] require experience and involve a
certain degree of interpretation. The subjectivity involved
can only be minimized by an optimized training of expe-
rienced analysts. Finally, signal intensity analysis with
current CE-CMR techniques do not incorporate areas of
microvascular obstruction, which are hypo-enhanced in
CE-CMR [31], which may lead to underestimation of
infarct size. As only one patient of the present patient
population showed microvascular obstruction, the micro-
vascular incorporated to obstruction area was not the
infarct core.
While CMR is the gold standard for the assessment of
LV function, myocardial viability, extent and transmurality
of scar, our findings suggest that infarct tissue analysis with
the CE-CMR technique that is currently applied in clinical
practice does not appear to have the potential to improve
the current practice of risk stratification in MI patients
considered for ICD implantation.
Limitations
Our study comprises a limited number of patients; never-
theless, this represents a consecutive series of patients
examined with CE-CMR for that indication. While the
secondary outcome of defibrillator shocks was prospec-
tively collected and analyzed, the primary comparison of
CE-CMR image characteristics was based on a cross-sec-
tional approach. In the light of the duration of clinical
follow-up of 21 ± 9 months, event rates in subgroups
should be interpreted carefully. In addition, primary aim of
the present study was the assessment of potential differ-
ences in infarct tissue characteristics between ICD recipi-
ents for primary versus secondary prevention.
Conclusion
There was no difference in infarct tissue characteristics
between recipients of ICD for primary versus secondary
prevention, while the secondary prevention group showed a
higher frequency of applied ICD therapy for ventricular
arrhythmia.
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